Skip to main content
Top

Supportive Care in Cancer

Issue 4/1999

Content (16 Articles)

EDITORIAL

Dyspnea in cancer patients

P. Drings

EDITORIAL

Oral infection

D. E. Peterson

SUPPORTIVE CARE INTERNATIONAL

Palliative care in the University Hospital Lausanne: from consultations to an integrated regional program

C. Mazzocato, F. Stiefel, S. Ducret, A. Vagnair

REVIEW ARTICLE

Assessment of dyspnea in advanced cancer patients

I. Mancini, J. J. Body

ORIGINAL ARTICLE

Low-energy He/Ne laser in the prevention of radiation-induced mucositis

R. J. Bensadoun, J. C. Franquin, G. Ciais, V. Darcourt, M. M. Schubert, M. Viot, J. Dejou, C. Tardieu, K. Benezery, T. D. Nguyen, Y. Laudoyer, O. Dassonville, G. Poissonnet, J. Vallicioni, A. Thyss, M. Hamdi, P. Chauvel, F. Demard

ORIGINAL ARTICLE

Analysis of early infectious complications in pediatric patients undergoing bone marrow transplantation

A. Busca, Eugenia M. Saroglia, Mareva Giacchino, Sergio Vai, Elena Vassallo, Franca Fagioli, Alessandra Linari, Giulia Dotti, Roberto Miniero, Enrico Madon

ORIGINAL ARTICLE

Granulocyte-colony stimulating factor for the prevention of chemotherapy-induced febrile neutropenia in the adult cancer patient population of Southern Israel

Jacob Gilad, Klaris Riesenberg, Wilmosh Mermershtain, Abraham Borer, Avi Porath, F. Schlaeffer

ORIGINAL ARTICLE

The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain

Bruno Gagnon, Monique Bielech, Sharon Watanabe, Paul Walker, John Hanson, E. Bruera

SHORT COMMUNICATION

Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain

Eduardo Bruera, Michelle Belzile, Catherine M. Neumann, I. Ford, Zoltan Harsanyi, Andrew Darke

SHORT COMMUNICATION

Allergic reaction to the liposomal component of liposomal amphotericin B

S. Cesaro, Elisabetta Calore, Chiara Messina, Luigi Zanesco

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine